Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-Year follow-up study

Gastroenterologia y Hepatologia

Volumn 31, Issue 8, 2008, Pages 477-484

  Gisbert, Javier P ^a,b   Luna, Marta ^a   González Lama, Yago ^a   Pousa, Inés D ^a   Velasco, Marta ^a   Moreno Otero, Ricardo ^a   Maté, José ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Urb Bonanza   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CROHN DISEASE; DRUG EFFECT; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONITORING; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; UNIVARIATE ANALYSIS;

EID: 59949105013     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13127088     Document Type: Article

References (86)

1. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2002: CD000544.
2. Gisbert JP, Gomollon F, Mate J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci. 2002;47:471-88.
3. Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:1-6.
4. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004; 19:179-89.
5. Gisbert JP, González-Lama Y, Maté J. 5-aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007;13:629-38.
6. Calder IC, Funder CC, Green CR, Ham KN, Tange JD. Nephrotoxic lesions from 5-aminosalicylic acid. Br Med J. 1972;1:52-4.
7. Bilyard KG, Joseph EC, Metcalf R. Mesalazine: an overview of key preclinical studies. Scand J Gastroenterol. 1990;172 Suppl:52-5.
8. World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant. 1996;11:614-21.
9. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;170 Suppl:2-6; discussion 16-19.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
11. Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical practice. BMJ. 2006;333:733-7.
12. Fockens P, Mulder CJ, Tytgat GN, Blok P, Ferwerda J, Meuwissen SG, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group [see comments]. Eur J Gastroenterol Hepatol. 1995;7:1025-30.
13. Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther. 1996;10:949-56.
14. Walker AM, Szneke P, Bianchi LA, Field LG, Sutherland LR, Dreyer NA. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol. 1997;92:816-20.
15. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536-9.
16. Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:647-62.
17. Logan RF, van Staa TP. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2003;52:1530 [author reply 1530-1].
18. Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004;126:1733-9.
19. Elseviers MM, D'Haens G, Lerebours E, Plane C, Stolear JC, Riegler G, et al. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin Nephrol. 2004;61:83-9.
20. Muller AF, Stevens PE, McIntyre AS, Ellison H, Logan RF. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther. 2005;21:1217-24.
21. Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut. 1992;33:1348-52.
22. Birketvedt GS, Berg KJ, Fausa O, Florholmen J. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis. Inflamm Bowel Dis. 2000;6:275-9.
23. Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis [see comments]. Lancet. 1992;339:1279-81.
24. De Jong DJ, Tielen J, Habraken CM, Wetzels JF, Naber AH. 5-Aminosalicylates and effects on renal function in patients with Crohn's disease. Inflamm Bowel Dis. 2005;11:972-6.
25. Diener U, Tuczek HV, Fischer C, Maier K, Klotz U. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol. 1984;326:278-82.
26. Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther. 2001;15:1131-7.
27. Gendre JP, Mary JY, Florent C, Modigliani R, Colombel JF, Soule JC, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) [see comments]. Gastroenterology. 1993;104:435-9.
28. Giaffer MH, Holdsworth CD, Lennard-Jones JE, Rodrigues CA, McIntyre PB, Manjunatha S, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther. 1992;6:479-85.
29. Green JR, Swan CH, Rowlinson A, Gibson JA, Brown P, Kerr GD, et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther. 1992;6:647-52.
30. Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator Group. Aliment Pharmacol Ther. 1998;12:1207-16.
31. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group for Ulcerative Colitis. Gastroenterology. 1997; 112:718-24.
32. Ireland A, Mason C, Jewell D. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988;29:835-7.
33. Kiilerich S, Ladefoged K, Rannem T, Ranlov PJ. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Gut. 1992;33:252-5.
34. Kruis W, Judmaier G, Kayasseh L, Stolte M, Theuer D, Scheurlen C, et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol. 1995;7:391-6.
35. Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ther. 2002;16:207-15.
36. McIntyre PB, Rodrigues CA, Lennard-Jones JE, Barrison IG, Walker JG, Baron JH, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther. 1988;2:237-43.
37. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group [see comments]. Ann Intern Med. 1996;124:204-11.
38. Monteleone G, Cristina G, Parrello T, Morano S, Biancone L, Pietravalle P, et al. Altered IgG(4) renal clearance in patients with inflammatory bowel diseases. Evidence for a subclinical impairment of protein charge renal selectivity. Nephrol Dial Transplant. 2000;15:498-501.
39. Mulder CJ, Tytgat GN, Weterman IT, Dekker W, Blok P, Schrijver M, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis [see comments]. Gastroenterology. 1988;95:1449-53.
40. Poulou AC, Goumas KE, Dandakis DC, Tyrmpas I, Panagiotaki M, Georgouli A, et al. Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J Gastroenterol. 2006;12:739-46.
41. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-6.
42. Rijk MC, Van Lier HJ, Van Tongeren JH. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double- blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group. Am J Gastroenterol. 1992;87:438-42.
43. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988;29:669-74.
44. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94:1383-9.
45. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment Pharmacol Ther. 1989;3:183-91.
46. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology. 1986;90:1024-30.
47. Schreiber S, Hamling J, Zehnter E, Howaldt S, Daerr W, Raedler A, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut. 1997;40:761-6.
48. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9.
49. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group [see comments]. Gastroenterology. 1993;104:1293-301.
50. Siveke JT, Egert J, Sitter T, Schiemann U, Walcher P, Torok HP, et al. 5-ASA therapy and renal function in inflammatory bowel disease. Am J Gastroenterol. 2005;100:501.
51. Thomson AB, Wright JP, Vatn M, Bailey RJ, Rachmilewitz D, Adler M, et al. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther. 1995;9:673-83.
52. Agharazii M, Marcotte J, Boucher D, Noel R, Lebel M. Chronic interstitial nephritis due to 5-aminosalicylic acid. Am J Nephrol. 1999;19:373-6.
53. Arend LJ, Springate JE. Interstitial nephritis from mesalazine: case report and literature review. Pediatr Nephrol. 2004;19:550-3.
54. Behrens R, Ruder H. Chronic inflammatory intestinal disease and nephritis. Klin Padiatr. 1992;204:61-4.
55. Bonet J, Vaquero M, Bayes B, Romero R. [Renal involvement in patients with chronic inflammatory intestinal disease treated with mesalazine. How to prevent its nephrotoxicity?] [letter]. Med Clin (Barc). 1999;113:199.
56. Brouillard M, Gheerbrant JD, Gheysens Y, Fleury D, Devred M, Hazzan M, et al. Chronic interstitial nephritis and mesalazine: 3 new cases? Gastroenterol Clin Biol. 1998;22:724-6.
57. Calvino J, Romero R, Pintos E, Losada E, Novoa D, Guimil D, et al. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin Nephrol. 1998;49:265-7.
58. Colombel JF, Brabant G, Gubler MC, Locquet A, Comes MC, Dehennault M, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? [letter] [see comments]. Lancet. 1994;344:620-1.
59. De Broe ME, Stolear JC, Nouwen EJ, Elseviers MM. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link? Nephrol Dial Transplant. 1997;12:1839-41.
60. Fornaciari G, Maccari S, Borgatti PP, Rustichelli R, Amelio N, Lattuada I, et al. Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis. J Clin Gastroenterol. 1997;24:37-9.
61. Frandsen NE, Saugmann S, Marcussen N. Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron. 2002;92:200-2.
62. García-Díaz M, Nevado L, Berenguer A, Bureo JC, Bureo P, Sáenz de Santamaría J. [Acute renal failure associated with 5-aminosalicylic acid in inflammatory bowel disease]. Gastroenterol Hepatol. 1995;18:18-21.
63. Haas M, Shetye KR. Acute renal failure in a 53-year-old woman with Crohn's disease treated with 5-aminosalicylic acid. Am J Kidney Dis. 2001;38:205-9.
64. Hamling J, Raedler A, Helmchen U, Schreiber S. 5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease. Digestion. 1997;58:304-7.
65. Henning HV, Meinhold J, Eisenhauer T, Scheler F, Grone HJ. [Chronic interstitial nephritis after treatment with 5-aminosalicylic acid]. Dtsch Med Wochenschr. 1989;114:1091.
66. Howard G, Lynn KL. Renal dysfunction and the treatment of inflammatory bowel disease (IBD): a case for monitoring. Aust N Z J Med. 1998;28:346.
67. Laboudi A, Makdassi R, Cordonnier C, Fournier A, Choukroun G. Chronic interstitial nephritis induced by 5-aminosalicylic acid: a new case report. Nephrologie. 2002;23:343-7.
68. Maeda S, Nomura S, Tahara M, Haneda M, Kikkawa R. [Interstitial nephritis after treatment with mesalazine in the patient with ulcerative colitis]. Nippon Naika Gakkai Zasshi. 2001; 90:872-3.
69. Manenti L, De Rosa A, Buzio C. Mesalazine-associated interstitial nephritis: twice in the same patient. Nephrol Dial Transplant. 1997;12:2031.
70. Margetts PJ, Churchill DN, Alexopoulou I. Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. J Clin Gastroenterol. 2001;32:176-8.
71. Masson EA, Rhodes JM. Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut. 1992;33:563-4.
72. Mehta RP. Acute interstitial nephritis due to 5-aminosalicylic acid. CMAJ. 1990;143:1031-2.
73. Musil D. Early renal failure caused by mesalazine. Vnitr Lek. 2000;46:728-31.
74. Novis BH, Korzets Z, Chen P, Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. BMJ (Clin Res Ed). 1988;296:1442.
75. Ohya M, Otani H, Kimura K, Kodama N, Minami Y, Liang XM, et al. [Interstitial nephritis induced by mesalazine]. Nippon Jinzo Gakkai Shi. 2002;44:414-9.
76. Popoola J, Muller AF, Pollock L, O'Donnell P, Carmichael P, Stevens P. Late onset interstitial nephritis associated with mesalazine treatment. BMJ. 1998;317:795-7.
77. Ruf-Ballauf W, Hofstadter F, Krentz K. Acute interstitial nephritis caused by 5-aminosalicylic acid? Internist (Berl). 1989;30:262-4.
78. Smilde TJ, Van Liebergen FJ, Koolen MI, Gerlag PG, Assmann KJ, Berden JH. Tubulointerstitial nephritis caused by mesalazine (5-ASA) agents. Ned Tijdschr Geneeskd. 1994;138:2557-61.
79. Tadic M, Grgurevic I, Scukanec-Spoljar M, Bozic B, Marusic S, Horvatic I, et al. Acute interstitial nephritis due to mesalazine. Nephrology (Carlton). 2005;10:103-5.
80. Thuluvath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine induced interstitial nephritis. Gut. 1994;35:1493-6.
81. von Muhlendahl KE. [Nephritis from 5-aminosalicylic acid]. Dtsch Med Wochenschr. 1989;114:236.
82. Wilcox GM, Reynolds JR, Galvanek EG. Nephrotoxicity associated with olsalazine. Am J Med. 1996;100:238-40.
83. Witte T, Olbricht CJ, Koch KM. Interstitial nephritis associated with 5-aminosalicylic acid. Nephron. 1994;67:481-2.
84. Kreisel W, Wolf LM, Grotz W, Grieshaber M. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1996;8:461-8.
85. Payne RB. Creatinine clearance and glomerular filtration rate. Ann Clin Biochem. 2000;37:98-9.
86. Elseviers MM, De Broe ME. What can nephrologists learn from epidemiology? J Nephrol. 2001;14:88-92.